Clinical Trials Service s.r.o.

At Clinical Trials Service s.r.o. in Uherske Hradiste, research is centered on cardiovascular disease and nutritional and metabolic disease, with a strong focus on preventing major heart and vascular events and improving long-term risk control.

• Studies in atherosclerotic cardiovascular disease, high cardiovascular risk, and primary prevention are testing new ways to reduce heart attack, stroke, and urgent revascularization.
• Several trials target elevated lipoprotein(a) and dyslipidemia, aiming to improve lipid management and lower residual cardiovascular risk.
• Research also includes obesity, overweight, and type 2 diabetes, reflecting the link between metabolic health and cardiovascular outcomes.

These studies are designed to evaluate new therapies and better prevention strategies for people at risk of serious heart and metabolic complications.

This site is actively involved in trials focused on heart failure, including chronic heart failure, heart failure with preserved ejection fraction, and heart failure with mildly reduced ejection fraction, with the goal of improving outcomes for patients living with symptomatic disease.

• Research is examining treatments for heart failure with obesity and systemic inflammation, looking at ways to reduce hospitalizations and cardiovascular death.
• Some studies address heart failure in people with reduced pumping function, including those with additional conditions such as type 2 diabetes and hypertension.
• Other work evaluates supportive approaches for symptomatic chronic heart failure, including treatment strategies that may improve clinical stability and quality of life.

The overall purpose is to test therapies that may better control symptoms, prevent worsening heart failure, and reduce serious cardiac events.

Another important area at this Czechia site is hypertension, including difficult-to-control forms such as resistant hypertension and uncontrolled hypertension, where improved blood pressure management remains a major need.

• Trials are evaluating new options for people whose blood pressure stays above target despite standard treatment.
• Research includes patients with established cardiovascular disease and those at high risk, where better blood pressure control may help prevent future complications.
• These studies aim to assess whether novel therapies can provide safer and more effective control of systolic blood pressure.

In this field, the site is contributing to efforts to improve everyday treatment for patients with persistent hypertension and related cardiovascular risk.

A major research theme is the management of lipoprotein(a) and other lipid abnormalities, with studies designed to reduce cardiovascular events by targeting a key inherited risk factor.

• Trials are enrolling people with atherosclerotic cardiovascular disease and elevated Lp(a) to see whether new therapies can lower event rates.
• Work in dyslipidemia and hypercholesterolemia focuses on improving cholesterol control beyond standard care.
• Some studies include patients with obesity or overweight, reflecting the broader metabolic context of lipid-related risk.

These trials are intended to test whether advanced lipid-lowering approaches can better prevent first or recurrent major cardiovascular events.

The site also supports research in complex cardiometabolic disease and rare cardiac disorders, including ATTR amyloid cardiomyopathy, where treatment options remain limited and clinical need is high.

• Studies in obesity and metabolic disease are assessing therapies that may improve both cardiovascular outcomes and kidney-related health.
• Research in transthyretin amyloid cardiomyopathy is focused on reducing disease burden and improving survival in patients with hereditary or wild-type forms.
• Additional work explores whether newer treatments can support people with combined cardiovascular and metabolic risk factors.

Overall, the portfolio reflects a broad effort to evaluate innovative treatments across common and specialized heart-related conditions.